Your browser doesn't support javascript.
loading
Development of Novel Membrane Disrupting Lipoguanidine Compounds Sensitizing Gram-Negative Bacteria to Antibiotics.
Kim, Seong-Heun; Hind, Charlotte K; Fernandes, Guilherme F S; Wu, Jingyue; Semenya, Dorothy; Clifford, Melanie; Marsh, Caleb; Anselmi, Silvia; Mason, A James; Bruce, Kenneth D; Sutton, J Mark; Castagnolo, Daniele.
Afiliação
  • Kim SH; Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, United Kingdom.
  • Hind CK; Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
  • Fernandes GFS; Antimicrobial Discovery, Development and Diagnostics, Vaccine Development and Evaluation Centre, UKHSA Porton Down, Salisbury SP4 0JG, United Kingdom.
  • Wu J; Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, United Kingdom.
  • Semenya D; Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, United Kingdom.
  • Clifford M; Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
  • Marsh C; Antimicrobial Discovery, Development and Diagnostics, Vaccine Development and Evaluation Centre, UKHSA Porton Down, Salisbury SP4 0JG, United Kingdom.
  • Anselmi S; Antimicrobial Discovery, Development and Diagnostics, Vaccine Development and Evaluation Centre, UKHSA Porton Down, Salisbury SP4 0JG, United Kingdom.
  • Mason AJ; Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, United Kingdom.
  • Bruce KD; Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
  • Sutton JM; Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
  • Castagnolo D; Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
ACS Med Chem Lett ; 15(2): 239-249, 2024 Feb 08.
Article em En | MEDLINE | ID: mdl-38352828
ABSTRACT
A new class of amphiphilic molecules, the lipoguanidines, designed as hybrids of guanidine and fatty acid compounds, has been synthesized and developed. The new molecules present both a guanidine polar head and a lipophilic tail that allow them to disrupt bacterial membranes and to sensitize Gram-negative bacteria to the action of the narrow-spectrum antibiotics rifampicin and novobiocin. The lipoguanidine 5g sensitizes Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli to rifampicin, thereby reducing the antibiotic minimum inhibitory concentrations (MIC) up to 256-fold. Similarly, 5g is able to potentiate novobiocin up to 64-fold, thereby showing a broad spectrum of antibiotic potentiating activity. Toxicity and mechanism studies revealed the potential of 5g to work synergistically with rifampicin through the disruption of bacterial membranes without affecting eukaryotic cells.

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido